DrugPatentWatch Database Preview
Guerbet Company Profile
What is the competitive landscape for GUERBET, and what generic and branded alternatives to GUERBET drugs are available?
GUERBET has four approved drugs.
Summary for Guerbet
| US Patents: | 0 |
| Tradenames: | 5 |
| Ingredients: | 4 |
| NDAs: | 4 |
| Drug Master File Entries: | 1 |
Drugs and US Patents for Guerbet
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Guerbet | LIPIODOL | ethiodized oil | OIL;INTRALYMPHATIC, INTRAUTERINE | 009190-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Guerbet | OXILAN-350 | ioxilan | INJECTABLE;INJECTION | 020316-002 | Dec 21, 1995 | DISCN | No | No | Start Trial | Start Trial | |||||
| Guerbet | DOTAREM | gadoterate meglumine | SOLUTION;INTRAVENOUS | 204781-002 | Mar 20, 2013 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Guerbet | OXILAN-300 | ioxilan | INJECTABLE;INJECTION | 020316-001 | Dec 21, 1995 | DISCN | No | No | Start Trial | Start Trial | |||||
| Guerbet | DOTAREM | gadoterate meglumine | SOLUTION;INTRAVENOUS | 204781-004 | Mar 20, 2013 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Guerbet | DOTAREM | gadoterate meglumine | SOLUTION;INTRAVENOUS | 204781-003 | Mar 20, 2013 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Guerbet | DOTAREM | gadoterate meglumine | SOLUTION;INTRAVENOUS | 204781-001 | Mar 20, 2013 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Guerbet
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Guerbet | HEXABRIX | ioxaglate meglumine; ioxaglate sodium | INJECTABLE;INJECTION | 018905-002 | Jul 26, 1985 | 4,014,986 | Start Trial |
| Guerbet | OXILAN-300 | ioxilan | INJECTABLE;INJECTION | 020316-001 | Dec 21, 1995 | 4,954,348 | Start Trial |
| Guerbet | HEXABRIX | ioxaglate meglumine; ioxaglate sodium | INJECTABLE;INJECTION | 018905-002 | Jul 26, 1985 | 4,094,966 | Start Trial |
| Guerbet | OXILAN-350 | ioxilan | INJECTABLE;INJECTION | 020316-002 | Dec 21, 1995 | 4,954,348 | Start Trial |
| Guerbet | HEXABRIX | ioxaglate meglumine; ioxaglate sodium | INJECTABLE;INJECTION | 018905-002 | Jul 26, 1985 | 4,065,554 | Start Trial |
| Guerbet | HEXABRIX | ioxaglate meglumine; ioxaglate sodium | INJECTABLE;INJECTION | 018905-002 | Jul 26, 1985 | 4,065,553 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
